+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vaginitis Therapeutics Market by Treatment Type, Route Of Administration, Product Type, Distribution Channel, End User Demographics - Global Forecast to 2030- Product Image
Vaginitis Therapeutics Market by Treatment Type, Route Of Administration, Product Type, Distribution Channel, End User Demographics - Global Forecast to 2030- Product Image
Sale

Vaginitis Therapeutics Market by Treatment Type, Route Of Administration, Product Type, Distribution Channel, End User Demographics - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888952
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Vaginitis Therapeutics Market grew from USD 2.76 billion in 2024 to USD 3.02 billion in 2025. It is expected to continue growing at a CAGR of 9.21%, reaching USD 4.68 billion by 2030.

Setting the Stage for a Transformative Vaginitis Therapeutics Landscape

Vaginitis remains one of the most prevalent gynecological conditions, impacting millions of women across diverse demographics and presenting a significant burden on healthcare systems globally. Rising awareness of the condition’s multifactorial etiology, including microbial imbalances, hormonal fluctuations, and lifestyle influences, has catalyzed innovation in both diagnostics and therapeutics. In addition to conventional antifungal regimens, emerging probiotic formulations and personalized treatment plans are reshaping clinical pathways. This executive summary synthesizes critical findings, distilling the most impactful trends, regulatory shifts, and competitive dynamics currently shaping the market. By offering a clear, concise overview of the drivers, barriers, and strategic implications, this introduction equips decision-makers with the contextual foundation necessary to navigate a rapidly evolving landscape. Consequently, stakeholders can better align investment priorities, optimize product development roadmaps, and anticipate shifts in payer and patient expectations. The subsequent sections delve into transformative industry shifts, tariff considerations, segmentation insights, regional nuances, competitive positioning, and strategic recommendations-culminating in a holistic view that bridges market intelligence with actionable guidance.

Emerging Paradigms Shaping Vaginitis Management

The vaginitis therapeutics market is undergoing a paradigm shift as personalized medicine and microbiome-centered interventions gain traction alongside traditional therapies. Innovations in diagnostic platforms now enable rapid, point-of-care detection of specific pathogens, facilitating tailored treatment regimens rather than one-size-fits-all approaches. Meanwhile, research into probiotic treatments is redefining understanding of vaginal ecology, driving interest in preventive as well as curative solutions. Digital health integration, from telemedicine consultations to mobile adherence tracking, is enhancing patient engagement and expanding access, particularly in underserved regions. At the same time, regulatory frameworks are adapting to accommodate combination products and novel delivery mechanisms, accelerating time-to-market for innovative therapies. Collaborative partnerships between pharmaceutical companies, biotech firms, and academic institutions are fostering cross-disciplinary breakthroughs, while strategic licensing agreements are streamlining pipeline development. Together, these shifts are setting the stage for a market characterized by higher efficacy standards, deeper patient centricity, and more efficient commercialization pathways, ultimately promising improved outcomes and sustainable growth.

Assessing the Cumulative Impact of New US Tariffs

In 2025, newly instituted United States tariffs on active pharmaceutical ingredients and certain excipients have introduced fresh complexities into the cost structure of vaginitis treatments. Manufacturers face elevated import duties that challenge margins and incentivize supply chain realignment toward domestic production or alternative sourcing. These changes have prompted many organizations to reevaluate pricing strategies, with some electing selective cost absorption to preserve patient affordability while others are passing incremental expenses onto payers. The net effect has been greater negotiation volatility with pharmacy benefit managers and a renewed focus on formulary positioning. Meanwhile, in response to potential disruptions, firms are diversifying supplier networks and investing in vertical integration to mitigate supply risk. This tariff environment is also accelerating interest in local manufacturing incentives and capacity expansion in tariff-exempt jurisdictions. Over the long term, the cumulative impact of these policies may influence the global competitive balance, encouraging a shift in research and production hubs. As stakeholders adapt, agility in procurement, agile pricing models, and enhanced transparency across the value chain will prove critical to sustaining market momentum.

Decoding Market Dynamics Through Treatment, Administration, and Demographic Lenses

A nuanced understanding of the vaginitis therapeutics market emerges when examined through multiple segmentation lenses. Treatment options are divided between antifungal therapies and probiotic interventions, with the former encompassing both azole agents-such as clotrimazole, fluconazole, and miconazole-and polyene compounds including amphotericin B and nystatin, while the latter focuses on beneficial microbial formulations. Administration routes further delineate the landscape into intravaginal delivery via creams, gels, and suppositories; oral ingestion through capsules and tablets; and topical applications across various semisolid matrices. Market channels distinguish between over-the-counter accessibility and prescription-only offerings, reflecting differences in regulatory pathways, patient self-care dynamics, and reimbursement criteria. Distribution networks span hospital pharmacies, online platforms, and traditional retail outlets, each presenting unique logistical considerations and customer touchpoints. Finally, end-user demographics span post-menopausal women, segmented into ages 46-60 and 60 and above; pre-menopausal cohorts covering ages 18-25, 26-35, and 36-45; and pregnant women, whose therapeutic needs are shaped by safety profiles and clinical guidelines. Collectively, this multi-dimensional segmentation framework enables tailored go-to-market strategies and precise alignment of product attributes with patient and stakeholder expectations.

Regional Nuances Driving Vaginitis Therapeutic Uptake

Geographic nuances exert a profound influence on the adoption and evolution of vaginitis therapeutics. In the Americas, robust pharmaceutical infrastructure, high awareness of women’s health issues, and mature over-the-counter markets drive widespread availability of both generic antifungals and emerging probiotics. Regulatory pathways are well-established, facilitating rapid product launches, though pricing pressures from payers and pharmacy benefit managers remain formidable. Across Europe, the Middle East, and Africa, regulatory harmonization under initiatives such as the European Medicines Agency streamlines cross-border approvals, yet heterogeneous reimbursement frameworks pose challenges for market consistency. In emerging markets within this region, expanding healthcare access and increasing investment in women’s health are unlocking growth potential. In the Asia-Pacific, rising healthcare expenditure, growing patient awareness, and stronger rural distribution networks are accelerating uptake of advanced therapeutics. Local manufacturing hubs are expanding capacity, while public-private partnerships propel educational campaigns and telemedicine solutions. Each regional ecosystem presents distinct regulatory, economic, and cultural factors, underscoring the importance of customized market entry strategies and strategic partnerships to optimize reach and impact.

Navigating Competitive Terrain: Profiling Leading Innovators

The competitive landscape is shaped by a spectrum of legacy pharmaceutical leaders, specialized biotech innovators, and agile generic manufacturers. Major industry players maintain extensive portfolios spanning first-line azole therapies and next-generation formulations, supported by global distribution networks and established relationships with payers. At the same time, emerging companies are carving niches through probiotic product development, novel combination therapies, and targeted delivery platforms that address unmet clinical needs. Strategic alliances and licensing agreements are common, enabling larger firms to augment their pipelines with disruptive technologies developed by smaller entities. In parallel, generic firms leverage cost efficiencies to supply high-volume, price-sensitive markets, particularly in regions with robust OTC channels. Competitive differentiation increasingly hinges on value-added services-such as digital adherence tools, patient support programs, and diagnostic partnerships-that enhance product efficacy and patient satisfaction. As research investments intensify in microbiome modulation and personalized medicine, the ability to pivot rapidly from R&D to commercialization will define the next generation of market leaders.

Strategic Imperatives for Seizing Market Leadership

Industry leaders should prioritize investment in targeted R&D initiatives that advance both antimicrobial potency and microbiome balance, ensuring products meet evolving clinical guidelines and patient preferences. Establishing strategic partnerships with diagnostic companies and telehealth providers can amplify patient engagement and accelerate time-to-therapy. In response to tariff-driven cost pressures, flexible pricing models-such as value-based contracts and tiered reimbursement schemes-can secure formulary placements while safeguarding affordability. Expanding manufacturing footprint through local or nearshoring investments will bolster supply chain resilience and mitigate import duty risks. Furthermore, tailored messaging and educational campaigns aimed at distinct demographic cohorts-ranging from younger pre-menopausal women to older and pregnant populations-can deepen market penetration. Finally, leveraging real-world evidence and health economic data will strengthen negotiations with payers and support market access efforts, positioning new products as both clinically superior and cost-effective solutions.

Rigorous Methodology Underpinning Our Insights

This analysis draws upon a robust, mixed-methodology research framework combining comprehensive secondary data review and targeted primary investigations. Secondary sources include peer-reviewed journals, regulatory filings, company financial statements, and market intelligence reports. Primary research involved in-depth interviews with key opinion leaders, including gynecologists, microbiome researchers, payers, and distribution experts, to validate market assumptions and uncover emerging trends. Quantitative modeling techniques were applied to historical data and tariff scenarios, while qualitative thematic analysis identified strategic imperatives and competitive differentiators. Regional experts provided contextual insights into regulatory landscapes, reimbursement dynamics, and cultural attitudes toward women’s health. Throughout the process, findings were subjected to iterative validation cycles, ensuring accuracy, consistency, and relevance. This rigorous methodology underpins the strategic recommendations and in-depth segmentation and regional analyses presented herein, offering stakeholders a comprehensive and credible foundation for decision-making.

Synthesis of Findings and Strategic Outlook

The collective insights underscore a market at an inflection point, driven by technological innovation, shifting regulatory paradigms, and evolving patient expectations. Advanced diagnostic tools and microbiome-focused therapies are redefining clinical practice, while tariff adjustments are reshaping cost structures and supply chain strategies. Detailed segmentation analysis reveals opportunities to tailor interventions by treatment modality, administration route, product classification, distribution channel, and end-user demographics. Regional variations highlight the necessity of bespoke market approaches that align with distinct regulatory environments and healthcare infrastructures. Competitive dynamics favor organizations that blend legacy expertise with agile innovation, supported by strategic partnerships and differentiated patient services. By embracing the strategic imperatives outlined-ranging from localized manufacturing to digital engagement and value-based contracting-industry stakeholders can capture new growth avenues and sustain long-term leadership. This synthesis provides a roadmap for navigating current complexities and harnessing emerging opportunities in the vaginitis therapeutics landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Antifungal Treatments
      • Azoles
        • Clotrimazole
        • Fluconazole
        • Miconazole
      • Polyenes
        • Amphotericin B
        • Nystatin
    • Probiotic Treatments
  • Route Of Administration
    • Intravaginal
      • Creams
      • Gels
      • Suppositories
    • Oral
      • Capsules
      • Tablets
    • Topical
      • Creams
      • Gels
      • Ointments
  • Product Type
    • Over The Counter
    • Prescription
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User Demographics
    • Post-Menopausal Women
      • Age 46-60
      • Age 60+
    • Pre-Menopausal Women
      • Age 18-25
      • Age 26-35
      • Age 36-45
    • Pregnant Women
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • The Procter & Gamble Company
  • Bayer Aktiengesellschaft
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Vaginitis Therapeutics Market, by Treatment Type
8.1. Introduction
8.2. Antifungal Treatments
8.2.1. Azoles
8.2.1.1. Clotrimazole
8.2.1.2. Fluconazole
8.2.1.3. Miconazole
8.2.2. Polyenes
8.2.2.1. Amphotericin B
8.2.2.2. Nystatin
8.3. Probiotic Treatments
9. Vaginitis Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Intravaginal
9.2.1. Creams
9.2.2. Gels
9.2.3. Suppositories
9.3. Oral
9.3.1. Capsules
9.3.2. Tablets
9.4. Topical
9.4.1. Creams
9.4.2. Gels
9.4.3. Ointments
10. Vaginitis Therapeutics Market, by Product Type
10.1. Introduction
10.2. Over The Counter
10.3. Prescription
11. Vaginitis Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Vaginitis Therapeutics Market, by End User Demographics
12.1. Introduction
12.2. Post-Menopausal Women
12.2.1. Age 46-60
12.2.2. Age 60+
12.3. Pre-Menopausal Women
12.3.1. Age 18-25
12.3.2. Age 26-35
12.3.3. Age 36-45
12.4. Pregnant Women
13. Americas Vaginitis Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Vaginitis Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Vaginitis Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. The Procter & Gamble Company
16.3.3. Bayer Aktiengesellschaft
16.3.4. Teva Pharmaceutical Industries Ltd.
16.3.5. Viatris Inc.
16.3.6. Dr. Reddy's Laboratories Ltd.
16.3.7. Lupin Limited
16.3.8. Glenmark Pharmaceuticals Ltd.
16.3.9. Cipla Limited
16.3.10. Sun Pharmaceutical Industries Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VAGINITIS THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. VAGINITIS THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. VAGINITIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 80. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 82. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 83. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 84. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 86. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 87. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 88. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 91. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 92. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 93. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 96. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 97. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 99. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 100. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 101. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 105. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 159. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 161. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 162. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 163. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 165. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 166. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 167. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 171. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 172. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 174. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 175. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 176. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 178. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 179. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 180. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 184. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 198. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 200. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 201. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 202. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 204. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 205. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 206. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 209. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 210. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 211. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 213. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 214. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 215. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 217. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 218. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 219. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 223. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 263. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 265. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 266. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 267. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 269. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 270. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 271. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 275. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 289. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 291. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 292. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 293. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 295. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 296. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 297. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 300. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 301. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 302. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 304. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 305. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 306. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 308. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 309. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 310. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 313. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 314. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2030 (USD MILLION)
TABLE 315. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 316. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 318. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 319. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2030 (USD MILLION)
TABLE 321. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2

Companies Mentioned

The companies profiled in this Vaginitis Therapeutics market report include:
  • Pfizer Inc.
  • The Procter & Gamble Company
  • Bayer Aktiengesellschaft
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.02 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.68 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Vaginitis Therapeutics Market Report 2025 - Product Image

Vaginitis Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Vaginitis Therapeutics - Global Strategic Business Report - Product Image

Vaginitis Therapeutics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Vaginitis - Pipeline Insight, 2025 - Product Image

Vaginitis - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Vaginitis Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Vaginitis Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
Practical Guide to Obstetric and Gynecologic Dermatology - Product Image

Practical Guide to Obstetric and Gynecologic Dermatology

  • Book

About the Vaginitis Drug Market

Vaginitis Drug is a type of drug used to treat vaginitis, a condition characterized by inflammation of the vagina. Vaginitis is caused by a variety of factors, including bacterial, fungal, and viral infections, as well as hormonal imbalances. Vaginitis Drugs are used to treat the symptoms of vaginitis, such as itching, burning, and discharge. They may also be used to treat the underlying cause of the condition. Vaginitis Drugs are part of the larger Sexual and Reproductive Health Drugs market, which includes drugs used to treat a variety of conditions related to sexual and reproductive health, such as contraception, infertility, and sexually transmitted infections. Some companies in the Vaginitis Drug market include Pfizer, Merck, GlaxoSmithKline, Bayer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.